CVRx, Inc. Earnings Call Transcripts
Fiscal Year 2026
-
Leadership transition is underway with a structured CFO succession plan. Barostim therapy targets a $10B+ U.S. market, supported by strong clinical and real-world evidence. Improved reimbursement, a revamped sales force, and rising center productivity are driving 2024 growth, with a robust financial position and focus on U.S. expansion.
-
Barostim is positioned to address a large unmet need in heart failure, with strong clinical and real-world evidence supporting its efficacy and safety. Recent advances in reimbursement, including Humana's coverage, and ongoing trials could significantly expand its market and patient access.
-
The meeting confirmed quorum, elected three directors for three-year terms, and ratified the independent auditor. No questions were raised by stockholders, and forward-looking risks were highlighted in reference to the annual report.
-
Q1 2026 saw 20% revenue growth, improved gross margin, and narrowed net loss, with U.S. sales and reimbursement gains driving results. The launch of the BENEFIT-HF trial and transition to Category I CPT codes are expected to expand market opportunity and support long-term growth.
-
Barostim addresses a large, underserved heart failure market with strong clinical evidence and improved reimbursement, driving double-digit revenue growth and expanding its addressable market through a major new trial. Execution now focuses on salesforce productivity and deeper adoption.
Fiscal Year 2025
-
Q4 and full-year 2025 saw revenue growth and margin improvement, driven by sales force expansion and foundational investments. The transition to Category I CPT codes and the launch of the BENEFIT-HF trial are expected to accelerate growth and expand the addressable market in 2026 and beyond.
-
A major sales force transformation has set the stage for higher productivity, with new reps targeting $1.8 million in annual revenue per territory. Improved reimbursement, robust clinical evidence, and a large-scale RCT are expected to drive adoption and expand the addressable market.
-
A novel neuromodulation therapy for heart failure is showing strong clinical and real-world results, with significant improvements in quality of life and reduced hospitalizations. Strategic focus on high-opportunity centers and new reimbursement codes are expected to drive adoption and revenue growth.
-
Q3 2025 saw 10% revenue growth, margin expansion to 87%, and improved sales rep productivity. Guidance for 2025 was narrowed, with mid-teens growth targeted for 2026 as new reimbursement and sales initiatives take effect. Clinical trial expansion and strong cash position support future growth.
-
Barostim therapy targets a large, underserved heart failure market, showing strong clinical and real-world outcomes. Commercial execution is focused on sales force optimization and reimbursement wins, with financial stability and a major trial planned.
-
Q2 2025 revenue grew 15% year-over-year to $13.6 million, driven by U.S. heart failure business and expansion of implanting centers. Gross margin remained strong at 84%, while net loss was $14.7 million. Full-year revenue guidance was narrowed to $55–$57 million.
-
Barostim targets a $2.2B heart failure market with strong clinical results, including significant quality of life improvements and reduced hospitalizations. The company is transforming its salesforce, focusing on high-potential centers, and expects mid to high 20% long-term growth as reimbursement and access improve.
-
Q1 2025 revenue grew 15% year-over-year to $12.3 million, but sales force realignment and seasonality impacted results. Management expects productivity to improve as new hires ramp up, with full-year revenue guidance set at $55–$58 million and robust clinical evidence supporting Barostim adoption.
-
Barostim targets a large, underserved heart failure market with strong clinical evidence and improved reimbursement, driving 30%+ revenue growth and a focused U.S. expansion strategy. Utilization and deep adoption at select centers are key to scaling, with stable cash and a positive competitive outlook.
Fiscal Year 2024
-
Q4 2024 revenue grew 36% year-over-year, driven by U.S. heart failure segment expansion and improved reimbursement. 2025 guidance projects $63–$65M revenue, with focus on salesforce optimization, deeper center adoption, and continued clinical evidence generation.
-
Leadership highlighted strong market opportunity and impactful technology, with new executive hires and commercial focus on high-volume centers. Reimbursement stability and regulatory wins support growth, while financials remain strong with over two years of cash runway.
-
Q3 2024 revenue grew 27% year-over-year to $13.4 million, driven by strong U.S. heart failure business and key reimbursement wins. Net loss widened to $13.1 million, but cash reserves increased to $100.2 million, supporting continued investment and growth initiatives.
-
Barostim therapy addresses a large, underserved heart failure population with strong clinical results and a $2.2 billion U.S. market opportunity. The company is focusing on deepening adoption in existing accounts, supported by a new leadership team and ongoing evidence generation. Financially, it maintains a solid cash position and is navigating reimbursement challenges.
-
Q2 revenue grew 24% year-over-year to $11.8M, led by U.S. heart failure business and expanded sales force. Focus shifts to driving deeper utilization in existing accounts, while reimbursement changes pose both risks and opportunities. Cash burn improved, and 2024 guidance was reiterated.
-
New executive leadership is driving a focused strategy to expand Barostim therapy adoption, supported by strong clinical evidence, improved reimbursement, and robust financial growth. The company is targeting a $2.2 billion annual market with less than 2% current penetration and reaffirmed its 2024 revenue guidance.